A Multicenter, Open-Label, Phase Ii Trial Of S-1 Plus Carboplatin In Advanced Non-Small Cell Lung Cancer Patients With Interstitial Lung Disease

•The benefit of chemotherapy for advanced NSCLC patients with ILD remain unclear.•The efficacy of S-1 plus CBDCA in NSCLC patients with ILD was assessed in this study.•The overall response rate was 33.3%, which met the primary endpoint.•The incidence of AE-ILD was 6.1%, indicating the feasibility of S-1 plus CBDCA.•The combination of S-1 with CBDCA is a treatment option for NSCLC patients with ILD.